Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression

被引:0
作者
Patrick E Carroll
Masaru Okuda
Henning F Horn
Paul Biddinger
Peter J Stambrook
Lyon L Gleich
Ya-Qin Li
Pheruza Tarapore
Kenji Fukasawa
机构
[1] University of Cincinnati College of Medicine,Department of Cell Biology
[2] University of Cincinnati College of Medicine,Department of Pathology and Laboratory Medicine
[3] University of Cincinnati College of Medicine,Department of Otolaryngology
来源
Oncogene | 1999年 / 18卷
关键词
chromosome instability; p53; Mdm2; human cancer; centrosome hyperamplification;
D O I
暂无
中图分类号
学科分类号
摘要
We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperamplification, which leads to aberrant mitosis and chromosome instability. Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperamplification. Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperamplification is frequent in both tumor types. Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperamplification. However, in some cases, we observed centrosome hyperamplification in tumors that retained wild-type p53. These tumors contained high levels of Mdm2. Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperamplification. We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperamplification and chromosome instability in cultured cells.
引用
收藏
页码:1935 / 1944
页数:9
相关论文
共 50 条
  • [31] Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry
    Nenutil, R
    Smardova, J
    Pavlova, S
    Hanzelkova, Z
    Muller, P
    Fabian, P
    Hrstka, R
    Janotova, P
    Radina, M
    Lane, DP
    Coates, PJ
    Vojtesek, B
    JOURNAL OF PATHOLOGY, 2005, 207 (03) : 251 - 259
  • [32] Transcription factors that interact with p53 and Mdm2
    Inoue, Kazushi
    Fry, Elizabeth A.
    Frazier, Donna P.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (07) : 1577 - 1585
  • [33] Inhibition of p53 degradation by Mdm2 acetylation
    Wang, XJ
    Taplick, J
    Geva, N
    Oren, M
    FEBS LETTERS, 2004, 561 (1-3): : 195 - 201
  • [34] Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells
    Kao, Chia-Li
    Hsu, Han-Shui
    Chen, Hsin-Wu
    Cheng, Tzu-Hao
    CANCER LETTERS, 2009, 286 (02) : 250 - 259
  • [35] Mdm2 and MdmX partner to regulate p53
    Wang, Xinjiang
    Jiang, Xuejun
    FEBS LETTERS, 2012, 586 (10) : 1390 - 1396
  • [36] Mdm2: keeping p53 under control
    Jacques Piette
    Henry Neel
    Vincent Maréchal
    Oncogene, 1997, 15 : 1001 - 1010
  • [37] The p53 isoforms are differentially modified by Mdm2
    Camus, Suzanne
    Menendez, Sergio
    Fernandes, Kenneth
    Kua, Nelly
    Liu, Geng
    Xirodimas, Dimitris P.
    Lane, David P.
    Bourdon, Jean-Christophe
    CELL CYCLE, 2012, 11 (08) : 1646 - 1655
  • [38] The p53–Mdm2–HAUSP complex is involved in p53 stabilization by HAUSP
    C L Brooks
    M Li
    M Hu
    Y Shi
    W Gu
    Oncogene, 2007, 26 : 7262 - 7266
  • [39] Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features
    Horie, S
    Maeta, H
    Endo, K
    Ueta, T
    Takashima, K
    Terada, T
    PATHOLOGY INTERNATIONAL, 2001, 51 (01) : 11 - 15
  • [40] Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
    Unger, T
    Juven-Gershon, T
    Moallem, E
    Berger, M
    Sionov, RV
    Lozano, G
    Oren, M
    Haupt, Y
    EMBO JOURNAL, 1999, 18 (07) : 1805 - 1814